CVS Caremark will begin covering Eli Lilly’s weight-loss medication, Zepbound, starting October 1, 2026. This decision marks a significant reversal for the pharmacy benefits manager, which previously excluded the drug from its formulary. The move aligns CVS with the other two largest U.S. PBMs that already provide coverage for the treatment.
The expanded coverage represents a major commercial victory for Eli Lilly. It increases affordability and accessibility for millions of patients. This development will likely accelerate Zepbound's sales trajectory and strengthen Eli Lilly’s competitive position against Novo Nordisk in the anti-obesity market.
The news underscores increasing insurer acceptance of the medical necessity of these treatments. This shift remains a key factor for the long-term growth of the GLP-1 drug class.